Advertisement

Letter re: “Systematic review and non-inferiority meta-analysis of randomised phase II/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer”

  • Author Footnotes
    1 These authors contributed equally to the research.
    Chen Chang
    Footnotes
    1 These authors contributed equally to the research.
    Affiliations
    Department of Abdominal Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to the research.
    Zhaolun Cai
    Footnotes
    1 These authors contributed equally to the research.
    Affiliations
    Gastric Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China
    Search for articles by this author
  • Dan Cao
    Correspondence
    Corresponding author.
    Affiliations
    Department of Abdominal Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to the research.
Published:October 28, 2022DOI:https://doi.org/10.1016/j.ejca.2022.09.021
      We read with great interest the article by Derksen JWG et al. [
      • Derksen J.W.G.
      • Smit K.C.
      • May A.M.
      • Punt C.J.A.
      Systematic review and non-inferiority meta-analysis of randomised phase II/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer.
      ] The authors conducted a meta-analysis, which demonstrated that compared to 5-fluorouracil (5-FU)/capecitabine-based therapy, the S-1-based therapy showed non-inferiority for progression-free survival in patients with metastatic colorectal cancer. The study provided further evidence support for the clinical application of S-1. However, we have some concerns about the co-interventions in this study.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Derksen J.W.G.
        • Smit K.C.
        • May A.M.
        • Punt C.J.A.
        Systematic review and non-inferiority meta-analysis of randomised phase II/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer.
        Eur J Cancer. 2022 May; 166: 73-86
      1. Higgins J.P.T. Thomas J. Chandler J. Cumpston M. Li T. Page M.J. Welch V.A. Cochrane Handbook for systematic reviews of interventions version 6.3 (updated February 2022). Cochrane. 2022 (Available from:)
        • Abdel Shaheed C.
        • Blyth F.
        • Furmage A.M.
        • Stanaway F.
        Getting the "balance" right in clinical trials.
        BMJ. 2021 Nov 24; 375: n2869
        • Sackett D.L.
        Clinician-trialist rounds: 5. Cointervention bias--how to diagnose it in their trial and prevent it in yours.
        Clin Trials. 2011 Aug; 8: 440-442
        • McKenzie J.E.
        • Brennan S.E.
        • Ryan R.E.
        • Thomson H.J.
        • Johnston R.V.
        • Thomas J.
        Chapter 3: defining the criteria for including studies and how they will be grouped for the synthesis.
        (updated February 2022). Cochranein: Higgins J.P.T. Thomas J. Chandler J. Cumpston M. Li T. Page M.J. Welch V.A. Cochrane Handbook for systematic reviews of interventions version 6.3. 2022 (Available from:)
        • Yamada Y.
        • Denda T.
        • Gamoh M.
        • Iwanaga I.
        • Yuki S.
        • Shimodaira H.
        • et al.
        S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.
        Ann Oncol. 2018 Mar 1; 29: 624-631

      Linked Article